Designed to balance blood sugar levels in patients with type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists gained fame through a distinct and significant side effect: weight loss
Drucker has served as an advisor or consultant within the past 12 months to Arisaph Pharmaceuticals Inc., Intarcia Therapeutics Inc., Merck Research Laboratories, MedImmune, Novo Nordisk, NPS Pharmaceuticals Inc., Receptos Inc., Sanofi, Takeda, and Transition Therapeutics Inc
Research peptides may have limited stability data available, making appropriate storage and handling more challenging
Remember that mold detoxification is just one piece of the complex chronic illness puzzle
Another frequent consequence of aging is cognitive decline